Doubling adult stem cells outside the body for bone marrow regeneration
Peer-Reviewed Publication
Updates every hour. Last Updated: 3-May-2025 11:09 ET (3-May-2025 15:09 GMT/UTC)
An international research team, led by scientists from Tel Aviv University and Sheba Medical Center, has unveiled an innovative method for activating adult stem cells from human bone marrow, enabling their expansion outside the body for use in bone marrow regeneration and the construction of a new blood and immune system.
- A joint research team from DGIST, Kyungpook National University Chilgok Hospital, and Dongguk University has revealed the identity of cervical stem cells for the first time in the world - The research presents new possibilities for cervical cancer prevention and treatment using lactic acid bacteria and lactic acid, published in Nature Communications
A comprehensive study from Karolinska Institutet shows that people with fatty liver disease have almost twice the mortality rate of the general population. They have an increased risk of dying from both liver diseases and common diseases such as cancer and cardiovascular disease, according to the study published in The Journal of Hepatology.
A natural citrus oil from oranges, lemons, and limes is proving highly effective in relieving dry mouth, and when combined with a new lipid formulation, new research suggests it may be effective without significant side effects.
Developed by the University of South Australia in collaboration with the Medical School at Stanford University, this world first formulation uniquely combines limonene (a citrus essential oil) with a lipid-based drug delivery system to treat dry mouth (xerostomia), a common side effect of radiotherapy.
A simple urine test could accurately show the recurrence of kidney cancer at an early stage, potentially sparing patients invasive scans and enabling faster access to treatment, new research has shown.
An international collaborative research group led by Prof. Masatoshi Kudo, MD (Chair, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine) conducted a multicenter, randomized, double-blind, phase 3 study and demonstrated that the combination of the molecular targeted agent lenvatinib and the immune checkpoint inhibitor pembrolizumab in addition to the conventional treatment of transarterial chemoembolization (TACE) in patients with unresectable non-metastatic hepatocellular carcinoma (HCC) significantly extended progression-free survival and showed a trend toward extending overall survival compared to TACE alone. Based on the results of this study, it is anticipated that lenvatinib plus pembrolizumab, in combination with TACE, will become the standard of care for patients with unresectable non-metastatic HCC and may lead to a complete cure.
Biopsies guided by high resolution ultrasound are as effective as those using MRI in diagnosing prostate cancer, an international clinical trial has shown.